Advertisement
Advertisement

FHTX

FHTX logo

Foghorn Therapeutics Inc. Common Stock

5.73
USD
Sponsored
-0.04
-0.69%
Jan 30, 15:57 UTC -5
Closed
exchange

After-Market

5.71

-0.02
-0.26%

FHTX Earnings Reports

Positive Surprise Ratio

FHTX beat 14 of 21 last estimates.

67%

Next Report

Date of Next Report
Mar 04, 2026
Estimate for Q4 25 (Revenue/ EPS)
$9.69M
/
-$0.25
Implied change from Q3 25 (Revenue/ EPS)
+18.85%
/
--
Implied change from Q4 24 (Revenue/ EPS)
+239.28%
/
-16.67%

Foghorn Therapeutics Inc. Common Stock earnings per share and revenue

On Nov 05, 2025, FHTX reported earnings of -0.25 USD per share (EPS) for Q3 25, beating the estimate of -0.33 USD, resulting in a 26.36% surprise. Revenue reached 8.15 million, compared to an expected 6.32 million, with a 28.99% difference. The market reacted with a +13.31% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 12 analysts forecast an EPS of -0.25 USD, with revenue projected to reach 9.69 million USD, implying an increase of 0.00% EPS, and increase of 18.85% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Nurix Therapeutics, Inc. Common stock
Report Date
Jan 28, 2026 For Q4 25
Estimate
-$0.88
Actual
-$0.82
Surprise
+7.66%
logo
Regeneron Pharmaceuticals Inc
Report Date
Jan 30, 2026 For Q4 25
Estimate
$10.84
Actual
$11.44
Surprise
+5.52%
FAQ
For Q3 2025, Foghorn Therapeutics Inc. Common Stock reported EPS of -$0.25, beating estimates by 26.36%, and revenue of $8.15M, 28.99% above expectations.
The stock price moved up 13.31%, changed from $3.53 before the earnings release to $4.00 the day after.
The next earning report is scheduled for Mar 04, 2026.
Based on 12 analysts, Foghorn Therapeutics Inc. Common Stock is expected to report EPS of -$0.25 and revenue of $9.69M for Q4 2025.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement